TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$345.5 Million

IVERIC bio, Inc.

Follow-on Offering

Bookrunner, December 2022

IVERIC bio, Inc.

IVERIC bio, Inc. (“Company”) (ISEE) is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration.